Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 2...
May 12 2021 - 8:00AM
(NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on
gene-modified cellular and immune therapies in infectious diseases
and cancer, today announced the release of preliminary data
relating to the use of a novel cell therapy approach in controlling
human immunodeficiency virus (HIV) in humans. Dr. Serhat Gumrukçu,
co-founder and inventor of Enochian BioSciences and Director of the
Seraph Research Institute (SRI), presented the findings at the
Annual Meeting of the American Society of Gene and Cell Therapy
(ASGCT). Presentation can be found at
https://www.enochianbio.com/about-us/collaborations/
A 54-year-old man, diagnosed with HIV in 1986, had persistent
HIV detected in his blood, despite antiretroviral therapy. With
approval from an Institutional Review Board, this single patient
was treated with a novel cellular therapy of natural killer (NK)
and gamma delta T-cells (GDT) – a small subset of immune cells that
can be infected with HIV but could also be a key factor in
controlling the virus. The NK and GDT cells were collected from a
person who does not have HIV. Because the patient stopped antiviral
treatment and received some supportive medication before the
cellular therapy, the level of HIV initially increased, as
expected.
However, HIV levels began to decline after approximately three
weeks, and after 100 days dropped below the detection level of
routinely used blood tests (20 copies/ml). HIV levels in the
patient’s blood have remained at or below detection for an
additional 255 days, all while the patient has not been taking
antiviral medication.
This innovative cell therapy could be a potential strategy to
achieve a “functional cure” for HIV. This could potentially allow
persons living with HIV to stop antiviral treatment for extended
periods of time. Dr. Gumrukçu and SRI are currently pursuing a
regulatory pathway with the FDA to study the approach in more
patients. Enochian BioSciences holds the exclusive license for the
proprietary technology.
Dr. Mark Dybul, a prominent global HIV expert and Executive Vice
Chair of Enochian BioSciences said, “As an HIV researcher,
clinician and former leader of large, global HIV treatment
programs, I am excited by these results. Although antiviral
treatment is very effective, it is expensive and some patients
cannot, or do not want to receive it. This, combined with the fact
that access to antiviral treatments is limited, creates a
significant unmet medical need. While the findings presented are
preliminary and in one person with HIV, I’m hopeful that with
further testing in larger patient populations, SRI’s novel cell
therapy approach could one day be an alternative HIV treatment to
many.”
About Enochian BioSciences, Inc.Enochian
BioSciences, Inc. is a biopharmaceutical company dedicated to
identifying, developing, manufacturing, and commercializing
gene-modified cell therapy. The company’s gene-modified cell
therapy platform can be applied to multiple indications, including
HIV/AIDS and Oncology. For more information, please visit
www.enochianbio.com
About Seraph Research Institute (SRI)Seraph
Research Institute is a Los Angeles-based non-profit research
institution, which runs basic science, translational and clinical
research in pursuit of cures and effective treatments for chronic
viral infections, cancers, and genetic disorders. For more
information, please visit Seraphinstitute.org
Forward-Looking StatementsStatements in this
press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties, including but not limited to the
success or efficacy of our pipeline. All statements other than
historical facts are forward-looking statements, which can be
identified by the use of forward-looking terminology such as
“believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or
similar expressions. Actual events or results may differ materially
from those projected in any of such statements due to various
uncertainties, including as set forth in Enochian BioSciences’ most
recent Annual Report on Form 10-K filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. The findings in
this press release are preliminary and based on one person. There
is no assurance the findings will result in an effective
alternative treatment for HIV. All forward-looking statements are
qualified in their entirety by this cautionary statement, and
Enochian BioSciences undertakes no obligation to revise or update
this press release to reflect events or circumstances after the
date hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Sep 2023 to Sep 2024